PL2865391T3 - Sposób wytwarzania liofilizowanej kompozycji farmaceutycznej zawierającej mitomycynę C - Google Patents
Sposób wytwarzania liofilizowanej kompozycji farmaceutycznej zawierającej mitomycynę CInfo
- Publication number
- PL2865391T3 PL2865391T3 PL13189775T PL13189775T PL2865391T3 PL 2865391 T3 PL2865391 T3 PL 2865391T3 PL 13189775 T PL13189775 T PL 13189775T PL 13189775 T PL13189775 T PL 13189775T PL 2865391 T3 PL2865391 T3 PL 2865391T3
- Authority
- PL
- Poland
- Prior art keywords
- freeze
- producing
- pharmaceutical composition
- composition containing
- dried pharmaceutical
- Prior art date
Links
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 title 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 229960004857 mitomycin Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13189775.3A EP2865391B1 (de) | 2013-10-22 | 2013-10-22 | Verfahren zur Herstellung einer gefriergetrockneten pharmazeutischen Zusammensetzung mit Gehalt an Mitomycin C |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2865391T3 true PL2865391T3 (pl) | 2018-01-31 |
Family
ID=49515194
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13189775T PL2865391T3 (pl) | 2013-10-22 | 2013-10-22 | Sposób wytwarzania liofilizowanej kompozycji farmaceutycznej zawierającej mitomycynę C |
| PL17188743T PL3272361T3 (pl) | 2013-10-22 | 2013-10-22 | Sposób wytwarzania suszonej przez wymrażanie kompozycji farmaceutycznej zawierającej mitomycynę C |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17188743T PL3272361T3 (pl) | 2013-10-22 | 2013-10-22 | Sposób wytwarzania suszonej przez wymrażanie kompozycji farmaceutycznej zawierającej mitomycynę C |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10688049B2 (pl) |
| EP (2) | EP3272361B1 (pl) |
| JP (2) | JP6461945B2 (pl) |
| CN (1) | CN105744957B (pl) |
| DK (2) | DK2865391T3 (pl) |
| EA (1) | EA036982B1 (pl) |
| ES (2) | ES2771227T3 (pl) |
| LT (2) | LT3272361T (pl) |
| NO (1) | NO2865391T3 (pl) |
| PL (2) | PL2865391T3 (pl) |
| PT (2) | PT2865391T (pl) |
| WO (1) | WO2015059023A1 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10471150B2 (en) | 2010-01-20 | 2019-11-12 | Urogen Pharma Ltd. | Material and method for treating internal cavities |
| JP6706988B2 (ja) * | 2016-07-20 | 2020-06-10 | 日本化薬株式会社 | ボルテゾミブを含有する医薬組成物 |
| US20210169871A1 (en) * | 2018-04-05 | 2021-06-10 | Tarveda Therapeutics, Inc. | Pharmaceutical compositions with reduced tert-butanol levels |
| JP2023510258A (ja) * | 2020-01-10 | 2023-03-13 | アムジエン・インコーポレーテツド | 安定なシクロデキストリン不含カルフィルゾミブ処方物 |
| JP2023553976A (ja) * | 2020-12-11 | 2023-12-26 | ウロゲン ファーマ リミテッド | がんを治療するための材料及び方法 |
| CA3202582A1 (en) * | 2020-12-17 | 2022-06-23 | Edward J. Timm | Injection apparatus and method of use |
| CN113197870B (zh) * | 2021-04-14 | 2022-07-01 | 健进制药有限公司 | 一种注射用丝裂霉素冻干制剂及其制备方法 |
| IN202121042020A (pl) * | 2021-09-17 | 2023-03-24 | ||
| CN114557970B (zh) | 2022-03-17 | 2023-03-31 | 浙江长典药物技术开发有限公司 | 一种眼用丝裂霉素冻干粉及其制备方法 |
| WO2024079565A1 (en) * | 2022-10-12 | 2024-04-18 | Harshal Prabhakar Bhagwatwar | Stable mitomycin concentrates |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB830874A (en) | 1957-04-06 | 1960-03-23 | Kyowa Hakko Kogyo Kk | A new antibiotic mitomycin c and its production by fermentation |
| ZA86308B (en) * | 1985-02-25 | 1986-11-26 | Bristol Myers Co | In-vial deposition of 7-(dimethylaminomethylene)amino-9a-methoxy-mitosane |
| US5216011A (en) | 1989-09-01 | 1993-06-01 | Bristol-Myers Squibb Co. | Stable solutions of mitomycin c |
| KR100215739B1 (ko) * | 1994-10-13 | 1999-08-16 | 오쿠다 기요아키 | 가역성열겔화 수용성 의약 조성물을 함유하는 동결건조 제제 |
| DE19957371A1 (de) | 1999-11-29 | 2001-06-13 | Medac Klinische Spezialpraep | Mitomycin C-Lösung |
| SG161101A1 (en) | 2002-02-22 | 2010-05-27 | Schering Corp | Pharmaceutical formulations of antineoplastic agents, in particular temozolomide processes of making and using the same |
| CN1712014A (zh) * | 2004-06-14 | 2005-12-28 | 马文·F·刘 | 甘草甜素的新用途 |
| CN101204382A (zh) * | 2007-12-13 | 2008-06-25 | 厦门大学 | 植入型抗肿瘤药丝裂霉素双重缓释膜剂及其制备方法 |
| US8168224B2 (en) * | 2007-12-19 | 2012-05-01 | Beijing Shengyiyao Science & Technology Development Co., Ltd. | Sodium alginate microsphere vascular embolus containing water-soluble drug and preparation and application thereof |
-
2013
- 2013-10-22 PL PL13189775T patent/PL2865391T3/pl unknown
- 2013-10-22 EP EP17188743.3A patent/EP3272361B1/de active Active
- 2013-10-22 EP EP13189775.3A patent/EP2865391B1/de active Active
- 2013-10-22 PL PL17188743T patent/PL3272361T3/pl unknown
- 2013-10-22 ES ES17188743T patent/ES2771227T3/es active Active
- 2013-10-22 NO NO13189775A patent/NO2865391T3/no unknown
- 2013-10-22 DK DK13189775.3T patent/DK2865391T3/da active
- 2013-10-22 PT PT131897753T patent/PT2865391T/pt unknown
- 2013-10-22 DK DK17188743.3T patent/DK3272361T3/da active
- 2013-10-22 ES ES13189775.3T patent/ES2648367T3/es active Active
- 2013-10-22 PT PT171887433T patent/PT3272361T/pt unknown
- 2013-10-22 LT LTEP17188743.3T patent/LT3272361T/lt unknown
- 2013-10-22 LT LTEP13189775.3T patent/LT2865391T/lt unknown
-
2014
- 2014-10-16 JP JP2016525064A patent/JP6461945B2/ja active Active
- 2014-10-16 WO PCT/EP2014/072201 patent/WO2015059023A1/de not_active Ceased
- 2014-10-16 US US15/031,519 patent/US10688049B2/en active Active
- 2014-10-16 EA EA201690793A patent/EA036982B1/ru unknown
- 2014-10-16 CN CN201480057080.2A patent/CN105744957B/zh active Active
-
2018
- 2018-12-26 JP JP2018242147A patent/JP6869941B2/ja active Active
-
2020
- 2020-05-18 US US16/876,505 patent/US11766405B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2865391T3 (da) | 2017-11-20 |
| EP3272361A1 (de) | 2018-01-24 |
| US11766405B2 (en) | 2023-09-26 |
| ES2648367T3 (es) | 2018-01-02 |
| PT3272361T (pt) | 2020-01-21 |
| LT2865391T (lt) | 2017-11-27 |
| CN105744957A (zh) | 2016-07-06 |
| EP3272361B1 (de) | 2019-11-20 |
| LT3272361T (lt) | 2020-01-10 |
| US20160256391A1 (en) | 2016-09-08 |
| HK1208351A1 (en) | 2016-03-04 |
| JP6461945B2 (ja) | 2019-01-30 |
| DK3272361T3 (da) | 2020-01-27 |
| JP6869941B2 (ja) | 2021-05-12 |
| PT2865391T (pt) | 2017-12-22 |
| CN105744957B (zh) | 2019-07-02 |
| EA201690793A1 (ru) | 2016-08-31 |
| EP2865391B1 (de) | 2017-09-20 |
| JP2016534060A (ja) | 2016-11-04 |
| PL3272361T3 (pl) | 2020-04-30 |
| JP2019043969A (ja) | 2019-03-22 |
| NO2865391T3 (pl) | 2018-02-17 |
| US10688049B2 (en) | 2020-06-23 |
| WO2015059023A1 (de) | 2015-04-30 |
| ES2771227T3 (es) | 2020-07-06 |
| US20200276128A1 (en) | 2020-09-03 |
| EP2865391A1 (de) | 2015-04-29 |
| EA036982B1 (ru) | 2021-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201405323B (en) | New pyrrole compounds ,a process for their preparation and pharmaceutical compositions containing them | |
| LT2865391T (lt) | Liofilizuotos kompozicijos, turinčios mitomiciną c, gamybos būdas | |
| EP2961764A4 (en) | PROCESS FOR THE PRODUCTION OF TUBULYSINES | |
| IL243742A0 (en) | New indolizine compounds, a process for their preparation and pharmaceutical preparations containing them | |
| PL3262951T3 (pl) | Zaawansowane formowanie gum do żucia | |
| PL3046839T3 (pl) | Urządzenie do produkcji jednostek opakowań | |
| IL240214A0 (en) | A process for the preparation of enantiomerically enriched 3-aminopiperidine | |
| IL237075A0 (en) | A method for the production of the hexahydropyropyranol derivative | |
| IL241287A0 (en) | Processes for the preparation of subfervir | |
| EP2998395A4 (en) | METHOD FOR OBTAINING COMPOSITION CONTAINING LACTASE | |
| SG11201601477VA (en) | Pharmaceutical composition | |
| SG11201501567QA (en) | Method for producing 7-octenal | |
| IL239697A (en) | Process for making fluorolactone sequelae | |
| PL3089593T3 (pl) | Zaawansowane formowanie gum do żucia | |
| SG11201505385VA (en) | Pharmaceutical composition in the form of a tabletand a method for producing same | |
| PL2978321T3 (pl) | Sposób wytwarzania herbacianych produktów | |
| PL2996486T3 (pl) | Sposób otrzymywania kompozycji stewii | |
| PL3033946T3 (pl) | Sposób wytwarzania czekolady i czekolada wytworzona tym sposobem | |
| IL244365A0 (en) | pharmaceutical preparation | |
| GB201607411D0 (en) | Process for making confections | |
| IL234526A (en) | METHOD FOR PRODUCING DIETHINE TETRACARBOXIMIDES | |
| IL244646B (en) | Process for preparing 5-fluoro-1-alkyl-3-fluoroalkyl-1h-pyrazole-4-carbaldehyde | |
| PL2862891T3 (pl) | Sposób wytwarzania produktów syntetycznych | |
| IL239993A0 (en) | Process for preparing 5-fluoro-1-methyl-3-difluoromethyl-h1-pyrazole-4-carbaldehyde | |
| PL2732811T3 (pl) | Proces otrzymywania kompozycji liofilizowanej |